US Patent Issued to CANCER RESEARCH TECHNOLOGY on Dec. 30 for "Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2" (British Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,457, issued on Dec. 30, was assigned to CANCER RESEARCH TECHNOLOGY Ltd. (London).

"Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2" was invented by Mairi Sime (Glasgow, Great Britain) and Justin Bower (Glasgow, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are compounds of the Formula (I), and salts and solvates thereof: (Formula (I)) wherein R2, R3, X1, L, A, R6, R7 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, path...